Introducing New Prostate Cancer Treatment, Available from BioPlus

A new medication has joined the ranks of potential treatment for prostate cancer. The FDA recently approved Janssen’s Erleada™ (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but continues to grow despite treatment with hormone therapy (castration-resistant). BioPlus Specialty Pharmacy can help patients get started with Erleada and support them during the treatment process.

Erleada is only available through a limited distribution network of specialty pharmacies, which now includes BioPlus. This oral medication earned FDA approval months ahead of the scheduled decision date and is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer. The FDA’s fast approval turnaround of Erleada was based on clinical trials of this medication showing a 72% reduction in risk of metastasis or death. There are currently 2.9 million American men who were previously diagnosed with prostate cancer who are still alive. This medication will only be increasing this impressive number.

For men, prostate cancer remains the second most common type of cancer. Only skin cancer is more prevalent. Over the course of his lifetime, one in every seven men will develop prostate cancer and one in 39 men will die of prostate cancer. The difference in those numbers means that lots of men are surviving this disease and with Erleada now available those survival numbers should continue to go up.

Source

Press release. FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint. U.S. Food and Drug Administration February 14, 2018.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s